Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3σ

Baoguang Han, Han Xie, Qun Chen, Jian-Ting Zhang

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Advanced and hormone-refractory prostate cancer has long been considered as a chemoresistant disease. Recently, it was found that 14-3-3σ expression increases as prostate tumor progresses, and that 14-3-3σ contributes significantly to drug resistance in breast cancers. We, thus, hypothesized that advanced and hormone-refractory prostate cancers may have an increased level of 14-3-3σ, which in turn may contribute to drug resistance in advanced and hormone-refractory prostate cancers. In this study, we tested this hypothesis and found that, indeed, the expression level of 14-3-3σ in androgen-independent prostate cancer cell lines DU145, PC3, and CWR22RV are much higher than that in the androgen-dependent cell line LNCaP, and that the androgen-independent cells are more resistant to mitoxantrone and Adriamycin than the androgen-dependent cells. Depleting 14-3-3σ expression in DU145 and CWR22RV by RNA interference significantly sensitized these cells to mitoxantrone and Adriamycin by abrogating G2-M checkpoint and increasing apoptosis, whereas restoring 14-3-3σ expression in LNCaP cells enhanced drug resistance. We also showed that 14-3-3σ deficiency caused nuclear localization of Cdc2 and dephosphorylation of the Tyr15 residue upon DNA damage. Based on these studies, we propose that therapeutic intervention targeting 14-3-3σ may be useful for sensitizing hormone-refractory prostate cancers to chemotherapy by both G2-M checkpoint abrogation and apoptosis enhancement.

Original languageEnglish
Pages (from-to)903-912
Number of pages10
JournalMolecular Cancer Therapeutics
Volume5
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Drug Delivery Systems
Prostatic Neoplasms
Androgens
Hormones
Drug Resistance
Mitoxantrone
Doxorubicin
Apoptosis
Therapeutics
Cell Line
RNA Interference
DNA Damage
Prostate
Breast Neoplasms
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3σ. / Han, Baoguang; Xie, Han; Chen, Qun; Zhang, Jian-Ting.

In: Molecular Cancer Therapeutics, Vol. 5, No. 4, 04.2006, p. 903-912.

Research output: Contribution to journalArticle

Han, Baoguang ; Xie, Han ; Chen, Qun ; Zhang, Jian-Ting. / Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3σ. In: Molecular Cancer Therapeutics. 2006 ; Vol. 5, No. 4. pp. 903-912.
@article{15530b6934584b708eeec76bc3509822,
title = "Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3σ",
abstract = "Advanced and hormone-refractory prostate cancer has long been considered as a chemoresistant disease. Recently, it was found that 14-3-3σ expression increases as prostate tumor progresses, and that 14-3-3σ contributes significantly to drug resistance in breast cancers. We, thus, hypothesized that advanced and hormone-refractory prostate cancers may have an increased level of 14-3-3σ, which in turn may contribute to drug resistance in advanced and hormone-refractory prostate cancers. In this study, we tested this hypothesis and found that, indeed, the expression level of 14-3-3σ in androgen-independent prostate cancer cell lines DU145, PC3, and CWR22RV are much higher than that in the androgen-dependent cell line LNCaP, and that the androgen-independent cells are more resistant to mitoxantrone and Adriamycin than the androgen-dependent cells. Depleting 14-3-3σ expression in DU145 and CWR22RV by RNA interference significantly sensitized these cells to mitoxantrone and Adriamycin by abrogating G2-M checkpoint and increasing apoptosis, whereas restoring 14-3-3σ expression in LNCaP cells enhanced drug resistance. We also showed that 14-3-3σ deficiency caused nuclear localization of Cdc2 and dephosphorylation of the Tyr15 residue upon DNA damage. Based on these studies, we propose that therapeutic intervention targeting 14-3-3σ may be useful for sensitizing hormone-refractory prostate cancers to chemotherapy by both G2-M checkpoint abrogation and apoptosis enhancement.",
author = "Baoguang Han and Han Xie and Qun Chen and Jian-Ting Zhang",
year = "2006",
month = "4",
doi = "10.1158/1535-7163.MCT-05-0393",
language = "English",
volume = "5",
pages = "903--912",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3σ

AU - Han, Baoguang

AU - Xie, Han

AU - Chen, Qun

AU - Zhang, Jian-Ting

PY - 2006/4

Y1 - 2006/4

N2 - Advanced and hormone-refractory prostate cancer has long been considered as a chemoresistant disease. Recently, it was found that 14-3-3σ expression increases as prostate tumor progresses, and that 14-3-3σ contributes significantly to drug resistance in breast cancers. We, thus, hypothesized that advanced and hormone-refractory prostate cancers may have an increased level of 14-3-3σ, which in turn may contribute to drug resistance in advanced and hormone-refractory prostate cancers. In this study, we tested this hypothesis and found that, indeed, the expression level of 14-3-3σ in androgen-independent prostate cancer cell lines DU145, PC3, and CWR22RV are much higher than that in the androgen-dependent cell line LNCaP, and that the androgen-independent cells are more resistant to mitoxantrone and Adriamycin than the androgen-dependent cells. Depleting 14-3-3σ expression in DU145 and CWR22RV by RNA interference significantly sensitized these cells to mitoxantrone and Adriamycin by abrogating G2-M checkpoint and increasing apoptosis, whereas restoring 14-3-3σ expression in LNCaP cells enhanced drug resistance. We also showed that 14-3-3σ deficiency caused nuclear localization of Cdc2 and dephosphorylation of the Tyr15 residue upon DNA damage. Based on these studies, we propose that therapeutic intervention targeting 14-3-3σ may be useful for sensitizing hormone-refractory prostate cancers to chemotherapy by both G2-M checkpoint abrogation and apoptosis enhancement.

AB - Advanced and hormone-refractory prostate cancer has long been considered as a chemoresistant disease. Recently, it was found that 14-3-3σ expression increases as prostate tumor progresses, and that 14-3-3σ contributes significantly to drug resistance in breast cancers. We, thus, hypothesized that advanced and hormone-refractory prostate cancers may have an increased level of 14-3-3σ, which in turn may contribute to drug resistance in advanced and hormone-refractory prostate cancers. In this study, we tested this hypothesis and found that, indeed, the expression level of 14-3-3σ in androgen-independent prostate cancer cell lines DU145, PC3, and CWR22RV are much higher than that in the androgen-dependent cell line LNCaP, and that the androgen-independent cells are more resistant to mitoxantrone and Adriamycin than the androgen-dependent cells. Depleting 14-3-3σ expression in DU145 and CWR22RV by RNA interference significantly sensitized these cells to mitoxantrone and Adriamycin by abrogating G2-M checkpoint and increasing apoptosis, whereas restoring 14-3-3σ expression in LNCaP cells enhanced drug resistance. We also showed that 14-3-3σ deficiency caused nuclear localization of Cdc2 and dephosphorylation of the Tyr15 residue upon DNA damage. Based on these studies, we propose that therapeutic intervention targeting 14-3-3σ may be useful for sensitizing hormone-refractory prostate cancers to chemotherapy by both G2-M checkpoint abrogation and apoptosis enhancement.

UR - http://www.scopus.com/inward/record.url?scp=33645520585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645520585&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0393

DO - 10.1158/1535-7163.MCT-05-0393

M3 - Article

VL - 5

SP - 903

EP - 912

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -